- Home
- PM vs AZN Comparison
PM vs AZN Comparison
Compare PM & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PM
- AZN
- Stock Information
- Founded
- PM 1987
- AZN 1992
- Country
- PM United States
- AZN United Kingdom
- Employees
- PM N/A
- AZN N/A
- Industry
- PM Medicinal Chemicals and Botanical Products
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- PM Health Care
- AZN Health Care
- Exchange
- PM Nasdaq
- AZN Nasdaq
- Market Cap
- PM 239.5B
- AZN 205.5B
- IPO Year
- PM N/A
- AZN 1993
- Fundamental
- Price
- PM $169.59
- AZN $67.57
- Analyst Decision
- PM Buy
- AZN Strong Buy
- Analyst Count
- PM 11
- AZN 5
- Target Price
- PM $156.36
- AZN $92.33
- AVG Volume (30 Days)
- PM 6.4M
- AZN 5.2M
- Earning Date
- PM 04-23-2025
- AZN 04-29-2025
- Dividend Yield
- PM 3.18%
- AZN 2.28%
- EPS Growth
- PM N/A
- AZN 22.71
- EPS
- PM 4.86
- AZN 4.97
- Revenue
- PM $38,386,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- PM $10.06
- AZN $9.27
- Revenue Next Year
- PM $8.18
- AZN $6.02
- P/E Ratio
- PM $34.91
- AZN $13.61
- Revenue Growth
- PM 6.78
- AZN 15.48
- 52 Week Low
- PM $98.19
- AZN $61.24
- 52 Week High
- PM $176.49
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- PM 58.44
- AZN 41.25
- Support Level
- PM $168.89
- AZN $67.26
- Resistance Level
- PM $176.49
- AZN $72.69
- Average True Range (ATR)
- PM 3.12
- AZN 1.30
- MACD
- PM -0.11
- AZN -0.03
- Stochastic Oscillator
- PM 52.58
- AZN 12.03
About PM Philip Morris International Inc
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heatsticks, vapes, and oral nicotine offerings primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI has not only diversified away from smokeable products but also gained a toehold into the US to sell its iQOS heated tobacco product.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.